Beta Bionics, Inc.

Listed Company

BBNXCIK 0001674632NasdaqEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$100.25M

Net Income

$-73.20M

Total Assets

$328.74M

Equity

$287.61M

Shares Out

44.56M

Op. Cash Flow

$-50.92M

BBNX$17.29+31.28% · past yearDBEQ Basic

Daily closing prices

Business

Beta Bionics designs, develops, and commercializes the iLet Bionic Pancreas, a fully automated closed-loop insulin delivery system for insulin-requiring diabetes. The iLet received FDA clearance in May 2023 for Type 1 diabetes in adults and children age six and older. The company markets and distributes the device in the United States through a direct sales organization and independent distributors via durable medical equipment and pharmacy benefit plan channels. Pipeline products include the Mint tubeless patch pump and a bihormonal system combining insulin and glucagon delivery.

Summary from 10-K filed 2026-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Net sales	100	65	12
Cost of sales	45	29	6
Gross profit	56	36	6
Research and development	35	26	18
Sales and marketing	61	37	12
General and administrative	31	18	12
Total operating expenses	127	81	42
Loss from operations	−72	−45	−36
Interest income	11	4	2
Other expense	−1,000	−2,000	−68,000
Change in fair value of warrant liabilities	−12	−13	−10
Total other expense, net	−2	−10	−8
Net loss	−73	−55	−44
Unrealized gain (loss) on short-term and long-term investments	338,000	−72,000	137,000
Comprehensive loss	−73	−55	−44
Net loss per share attributable to common stockholders, basic	−1.81	−8.6	−8.31
Net loss per share attributable to common stockholders, diluted	−1.81	−8.6	−8.31
Weighted-average common shares outstanding, basic	41	6	5
Weighted-average common shares outstanding, diluted	41	6	5

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	32	30	27	—
Restricted cash, current	100,000	—	—	—
Short-term investments	188	73	70	—
Accounts receivable, net	17	12	4	—
Inventories, net	22	13	1	—
Prepaid expenses and other current assets	10	4	1	—
Total current assets	268	133	104	—
Property and equipment, net	9	5	2	—
Operating lease right-of-use asset	7	7	4	—
Restricted cash, noncurrent	—	100,000	100,000	—
Deferred offering costs	—	5	—	—
Long-term investments	45	—	—	—
Other long-term assets	180,000	150,000	121,000	—
Total assets	329	150	110	—
Accounts payable	5	3	1	—
Accrued expenses and other current liabilities	22	16	8	—
Operating lease liabilities	2	2	1	—
Deferred revenue	2	939,000	87,000	—
Total current liabilities	31	21	11	—
Operating lease liabilities, net of current portion	5	6	3	—
Deferred revenue, net of current portion	3	2	255,000	—
Warrant liabilities	—	45	38	—
Other long-term liabilities	2	—	—	—
Total liabilities	41	74	51	—
Commitments and contingencies (Note 18)	—	—	—	—
Convertible preferred stock (Series A, A-2, B, B-2, C, D and E), par value of $0.0001 per share; no and 34,966,547 shares authorized at December 31, 2025 and December 31,2024, respectively; no and 17,228,954 shares issued and outstanding at December 31, 2025 and December 31,2024, respectively; liquidation preference of no and $355,162 at December 31, 2025 and December 31,2024, respectively	—	321	262	—
Preferred stock	—	—	—	—
Common stock	4,000	1,000	—	—
Additional paid-in capital	657	51	26	—
Accumulated other comprehensive income	403,000	65,000	137,000	—
Accumulated deficit	−370	−297	−230	—
Total stockholders' equity (deficit)	288	−245	−203	−170
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	329	150	110	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Depreciation expense	2	1	1
Provision for expected credit losses	40,000	70,000	46,000
Stock-based compensation expense	16	6	6
Net provision for excess and obsolete inventory	1	−636,000	−58,000
Accretion of discount on short-term investments	−2	−3	−747,000
Amortization of premium on long-term investments	63,000	—	—
Amortization of operating lease right-of-use asset	1	1	865,000
Loss on disposal of property and equipment	31,000	23,000	11,000
Accounts receivable	−5	−8	−4
Inventories	−10	−11	−1
Prepaid expenses and other current assets	−6	−3	−391,000
Other long-term assets	−30,000	−29,000	−28,000
Accounts payable	2	2	716,000
Accrued expenses and other current liabilities	7	7	2
Other long-term liabilities	2	—	—
Operating lease liability	−1	−1	−948,000
Deferred revenue	2	2	342,000
Net cash used in operating activities	−51	−48	−32
Purchases of short-term investments	−282	−72	−69
Purchases of long-term investments	−45	—	—
Proceeds from maturities and redemptions of short-term investments	170	72	—
Proceeds on disposal of property and equipment	—	50,000	4,000
Purchases of property and equipment	−5	−3	−402,000
Net cash used in investing activities	−163	−3	−70
Proceeds from the issuance of common stock, net of underwriting discounts, commissions and issuance costs	195	—	—
Proceeds from the issuance of common stock from private placement, net of issuance costs	16	—	—
Proceeds from the issuance of convertible preferred stock, net of issuance costs	—	60	101
Payments for deferred offering costs	—	−4	—
Proceeds from stock option exercises	5	89,000	10,000
Proceeds from common stock warrants exercise	—	13,000	19,000
Net cash provided by financing activities	215	56	101
Net increase in cash, cash equivalents and restricted cash	1	4	−1
Deferred offering costs included in accrued expenses	—	862,000	—
Reclassification of long-term investments to short-term investments	171	—	—
Conversion of convertible preferred stock upon initial public offering	321	—	—
Conversion of warrants net exercise upon initial public offering	57	—	—
Reclassification of deferred offering costs to equity upon initial public offering	5	—	—
Operating lease right-of-use asset obtained in exchange for operating lease obligations	1	4	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Beta Bionics, Inc.'s CIK number?

Beta Bionics, Inc.'s SEC CIK number is 0001674632 (1674632). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Beta Bionics, Inc.'s SEC filings?

All of Beta Bionics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Beta Bionics, Inc. last report earnings?

Beta Bionics, Inc. (BBNX) most recently filed an earnings 8-K with the SEC on Apr 21, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001171843-26-002614). This is Beta Bionics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Beta Bionics, Inc.'s most recent earnings 8-K?

Beta Bionics, Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 21, 2026 under accession 0001171843-26-002614. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Beta Bionics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →